Sanofi to transfer 100 percent rights of Libtayo to Regeneron Ruchika Sharma3 Jun 2022 12:34 PM ISTUpon closing of the transaction, Regeneron will make an upfront payment of $900 million to Sanofi, which will be entitled to receive an 11% royalty on...
USFDA extends review of REGEN-COV to treat, prevent COVID-19: Regeneron Pharma Ruchika Sharma18 April 2022 10:00 AM ISTREGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies designed specifically to block infectivity of SARS-CoV-2 using...
Sanofi, Regeneron get CHMP recommendation for Dupixent approval to treat severe asthma with type 2 inflammation in kids Ruchika Sharma1 Feb 2022 10:00 AM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Medicines Agency's Committee for Medicinal Products for Human...
AstraZeneca, US strike deal for Covid-19 antibody treatment touted by Trump Ruchika Sharma11 Oct 2020 10:30 AM ISTAstraZeneca said it was planning to supply up to 1,00,000 doses starting toward the end of 2020 and that the U.S. government could acquire up to an...
Pharma firms test antibody drugs to treat, prevent Covid-19 Ruchika Sharma15 Aug 2020 9:00 AM ISTNew Delhi: With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies...
Sanofi-Regeneron Dupixent gets NMPA nod to treat atopic dermatitis Ruchika Sharma22 Jun 2020 10:30 AM ISTThe approval was based on positive data from the global LIBERTY AD clinical trial program that included nearly 3,000 patients with inadequately...
Sanofi plans to sell its equity investment in Regeneron; confirms no change to ongoing collaboration Hina Zahid27 May 2020 2:17 PM ISTParis: Sanofi has announced its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by...
Dupixent met co-primary endpoints in Part A of Phase 3 trial: Regeneron, Sanofi Ruchika Sharma25 May 2020 5:25 PM ISTDupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.
